Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 40.34B P/E 59.23 EPS this Y 7.80% Ern Qtrly Grth 14.10%
Income 681.8M Forward P/E 12.74 EPS next Y 6.20% 50D Avg Chg -
Sales 6.26B PEG 1.63 EPS past 5Y 17.70% 200D Avg Chg 10.00%
Dividend N/A Price/Book 3.25 EPS next 5Y 8.49% 52W High Chg -3.00%
Recommedations 2.70 Quick Ratio 3.47 Shares Outstanding 221.02M 52W Low Chg 83.00%
Insider Own 0.27% ROA 10.08% Shares Float 220.65M Beta 1.26
Inst Own 88.02% ROE 4.43% Shares Shorted/Prior -/- Price 182.50
Gross Margin 90.94% Profit Margin 10.89% Avg. Volume 4,222,993 Target Price 177.36
Oper. Margin 47.41% Earnings Date Oct 27 Volume 3 Change 0.00%
About Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.

ALXN Chatroom

User Image 11thestate Posted - 4 weeks ago

$ALXN will pay $125M to settle claims with shareholders over allegedly illegal sales strategies that caused a double-digit plunge in stock price. The claim deadline is already passed but you can file a late claim: https://11thestate.com/cases/alexion-shareholder-settlement

User Image TigerZen Posted - 2 months ago

$AKTX I am starting to think $ALXN most likely bought the rights to Nomacopan for HSCT-TMA therapy as it has a PRV voucher attached to it ($100M value) which would give the combined Peak BIO Akari company immediate cash that they need. This is based off an email I sent to Marc Dunoyer (Alexion CEO) and him relaying interest in Akari's nomacopan in a followup email which ultimately connected with Rachelle (Akari CEO).

User Image ca_rott1487 Posted - 3 months ago

$ALXN agreed to settle a $125M with shareholders to end claims that the company caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light. The deadline has passed but you can file for a late claim:https://11thestate.com/cases/alexion-shareholder-settlement

User Image fin_researcher Posted - 6 months ago

ðŸŽŊA Manhattan judge gave a former $ALXN executive eight months of #housearrest for sharing confidential information about the company's $1.4B #purchase. https://11thestate.com/cases/alexion-shareholder-settlement

User Image STCKPRO Posted - 7 months ago

$ALXN NEW ARTICLE : Doubling Down On Gain Therapeutics https://www.stck.pro/news/ALXN/70710340/

User Image Stan_Vick Posted - 7 months ago

ðŸ’ĩ Alexion pays $125 million to shareholders to end claims over illegal sales strategy. ⚠ïļ $ALXN payout claim deadline - December 15, 2023. Don't forget to take your share of settlement! https://11thestate.com/cases/alexion-shareholder-settlement

User Image fin_researcher Posted - 8 months ago

ðŸŽŊ#Lawfirms are seeking around $31M in attorney fees after securing a $125 million #settlement for $ALXN shareholders. https://11thestate.com/cases/alexion-shareholder-settlement

User Image JoeyTreg Posted - 9 months ago

$OMER From $alxn killer (ðŸ˜‚ðŸ‘ŒðŸ―) to Penny Stock 14 years of leadership from the Demopolous Douchebags!!! a pair of braindead idiots or full fledged scam artist? tell us what you think $GRTS

User Image JoeyTreg Posted - 9 months ago

$OMER bulls remember when dr scam said he felt bad for $ALXN ? because they only had Soliris? 😂😂😂😂 he said his goal was to be the biggest bio out of the northwest?! well, he was partially right hes the biggest bioSCAM out of the entire PLANET!!! $xbi 😂😂😂😂😂😂ðŸĪŠðŸĪŠðŸĪŠðŸĪŠ

User Image fin_researcher Posted - 9 months ago

$ALXN Alexion has reached a $125M million settlement with former shareholders to resolve the misleading lawsuit. If you have traded $ALXN you can claim your part of the settlement here: https://11thestate.com/cases/alexion-shareholder-settlement

User Image Stan_Vick Posted - 9 months ago

✅ Alexion settles a $125 million with investors to end claims that the $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light. ⚠ïļ Payout claim deadline - December 15, 2023! https://11thestate.com/cases/alexion-shareholder-settlement

User Image fin_researcher Posted - 9 months ago

$ALXN Alexion agreed to pay $125M to its former shareholders to end claims that $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light. If you have traded $ALXN you can claim your part of the settlement here: 11thestate.com/cases/alexion-shareholder-settlement

User Image DrEddySusman Posted - 9 months ago

@AlphaG assuming you are Canadian given the TSX listing of your suggestion and the Canada goose display. Canadian companies are always ripe for acquisition as the biotech ecosystem is small. Had great fortune of being in $TRIL and $ALXN in the early days. Will give it a close look. GL

User Image WarnedUBoutStoney Posted - 10 months ago

$ALXN Lol so even here, at the end of all things, Alexion is still a fucking scumbag company.

User Image KobyHiggins Posted - 10 months ago

$YYAI $ALXN $AABB Why are you paying for a trading room? We are opening our trading chat-room to the public'.🚀 https://amazing-stocks-market-today.blogspot.com/2023/09/stock-futures-hold-on-to-slender-gain.html

Analyst Ratings
SVB Leerink Market Perform Mar 23, 21
SVB Leerink Outperform Feb 5, 21
Raymond James Market Perform Jan 8, 21
Truist Securities Hold Dec 16, 20
Citigroup Neutral Dec 15, 20
Credit Suisse Neutral Dec 14, 20
BMO Capital Market Perform Dec 14, 20
Baird Neutral Dec 14, 20
SVB Leerink Outperform Dec 14, 20